Literature DB >> 21343463

Effect of ceftobiprole treatment on growth of and toxin production by Clostridium difficile in cecal contents of mice.

Michelle M Nerandzic1, Curtis J Donskey.   

Abstract

Ceftobiprole and ceftobiprole medocaril did not promote growth of or toxin production by Clostridium difficile in mouse cecal contents, whereas ceftazidime, cefoxitin, ceftriaxone, cefotaxime, and ertapenem did. The relatively low propensity of ceftobiprole to promote C. difficile was attributable to inhibitory activity against C. difficile and sparing of anaerobic microflora.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21343463      PMCID： PMC3088227          DOI： 10.1128/AAC.01612-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem.

Authors:  Dale N Gerding
Journal:  Clin Infect Dis       Date:  2004-02-11       Impact factor: 9.079

2.  Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice.

Authors:  Nicole J Pultz; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Effect of carbapenem administration on establishment of intestinal colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice.

Authors:  Usha Stiefel; Nicole J Pultz; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

4.  Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals.

Authors:  S Johnson; M H Samore; K A Farrow; G E Killgore; F C Tenover; D Lyras; J I Rood; P DeGirolami; A L Baltch; M E Rafferty; S M Pear; D N Gerding
Journal:  N Engl J Med       Date:  1999-11-25       Impact factor: 91.245

5.  Antianaerobe activity of ceftobiprole, a new broad-spectrum cephalosporin.

Authors:  Lois Ednie; Stuart Shapiro; Peter C Appelbaum
Journal:  Diagn Microbiol Infect Dis       Date:  2007-01-19       Impact factor: 2.803

6.  In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections.

Authors:  Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerin L Tyrrell; Helen T Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2006-09-18       Impact factor: 5.191

7.  Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production.

Authors:  Robin L P Jump; Yuejin Li; Michael J Pultz; Georgios Kypriotakis; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

8.  Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam.

Authors:  C D Settle; M H Wilcox; W N Fawley; O J Corrado; P M Hawkey
Journal:  Aliment Pharmacol Ther       Date:  1998-12       Impact factor: 8.171

9.  Risk factors for Clostridium difficile infection.

Authors:  G E Bignardi
Journal:  J Hosp Infect       Date:  1998-09       Impact factor: 3.926

10.  Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.

Authors:  Daniel A Adams; Michelle M Riggs; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2007-06-11       Impact factor: 5.191
View more
  12 in total

Review 1.  Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.

Authors:  Yahiya Y Syed
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

2.  The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection.

Authors:  Angela E Reeves; Casey M Theriot; Ingrid L Bergin; Gary B Huffnagle; Patrick D Schloss; Vincent B Young
Journal:  Gut Microbes       Date:  2011-05-01

3.  The ecology of antibiotic use in the ICU: homogeneous prescribing of cefepime but not tazocin selects for antibiotic resistant infection.

Authors:  Andrew N Ginn; Agnieszka M Wiklendt; Heather F Gidding; Narelle George; James S O'Driscoll; Sally R Partridge; Brian I O'Toole; Rita A Perri; Joan Faoagali; John E Gallagher; Jeffrey Lipman; Jonathan R Iredell
Journal:  PLoS One       Date:  2012-06-25       Impact factor: 3.240

4.  Association of tcdA+/tcdB+ Clostridium difficile Genotype with Emergence of Multidrug-Resistant Strains Conferring Metronidazole Resistant Phenotype.

Authors:  Farahnaz-Sadat Shayganmehr; Masoud Alebouyeh; Masoumeh Azimirad; Mohammad Mehdi Aslani; Mohammad Reza Zali
Journal:  Iran Biomed J       Date:  2015-06-06

Review 5.  Ceftobiprole for the treatment of pneumonia: a European perspective.

Authors:  Adamantia Liapikou; Catia Cillóniz; Antonio Torres
Journal:  Drug Des Devel Ther       Date:  2015-08-18       Impact factor: 4.162

6.  Subinhibitory antibiotic therapy alters recurrent urinary tract infection pathogenesis through modulation of bacterial virulence and host immunity.

Authors:  Lee W Goneau; Thomas J Hannan; Roderick A MacPhee; Drew J Schwartz; Jean M Macklaim; Gregory B Gloor; Hassan Razvi; Gregor Reid; Scott J Hultgren; Jeremy P Burton
Journal:  MBio       Date:  2015-03-31       Impact factor: 7.867

Review 7.  Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations.

Authors:  Antonio Torres; Johan Willem Mouton; Federico Pea
Journal:  Clin Pharmacokinet       Date:  2016-12       Impact factor: 6.447

8.  In Vitro Activity of Tedizolid, Dalbavancin, and Ceftobiprole Against Clostridium difficile.

Authors:  Dana Binyamin; Orna Nitzan; Maya Azrad; Zohar Hamo; Omry Koren; Avi Peretz
Journal:  Front Microbiol       Date:  2018-06-11       Impact factor: 5.640

Review 9.  Antimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile Infection.

Authors:  Simon D Baines; Mark H Wilcox
Journal:  Antibiotics (Basel)       Date:  2015-07-10

Review 10.  Role of cephalosporins in the era of Clostridium difficile infection.

Authors:  Mark H Wilcox; James D Chalmers; Carl E Nord; Jane Freeman; Emilio Bouza
Journal:  J Antimicrob Chemother       Date:  2016-09-22       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.